Vicious Cycle Between Alpha-Synuclein Aggregates and Glymphatic Impairment Proposed as Parkinson's Driver

The team used mouse models with alpha-synuclein overexpression and tracked cerebrospinal fluid flow via MRI and tracer injections. They measured reduced glymphatic clearance rates of 35-50% in affected animals compared to controls, correlating with faster motor decline. Human data came from postmortem tissue analysis showing meningeal vessel changes in Parkinson's cases.

This framing integrates prior glymphatic work from Maiken Nedergaard's group and alpha-synuclein seeding studies, suggesting inflammation from impaired waste removal amplifies protein misfolding rather than acting as a secondary effect. It challenges linear models where protein aggregation precedes all clearance deficits.

Therapeutic implications include testing lymphatic-enhancing compounds like VEGF-C alongside existing levodopa regimens. Early mouse data indicate partial restoration of flow slows aggregate spread, but translation requires accounting for age-related lymphatic decline in patients.

Next steps involve longitudinal PET imaging in at-risk cohorts to test whether clearance deficits precede clinical symptoms by measurable thresholds.